Inven2’s Board of Directors

Tom Pike is a life science industry professional holding board positions and other engagements related to the field. For many years he has worked to promote the health Industry in Norway, e.g. as co-initiator and member of the Norwegian governmental HealthCare21 Strategy Council, contributing to the BioVerdi report, mentor in the UiO SPARK program, etc.

He has over 30 years of experience in the health industry, including global responsibilities at Roche in Switzerland and as CEO of Roche Norway, Partner at the venture capital fund NeoMed and Chairman of the pharmaceutical industry association (LMI). For the past 13 years, the main focus has been on start-up companies in Norway and Sweden. He combines his board positions and consulting work with a part-time engagement at Oslo Metropolitan University working with innovation infrastructure. Tom Pike holds a B.Sc. Honors in pharmacology and has participated in a number of educational programs in business & administration, sales & marketing and finance.

Jens Petter Berg has been a professor of medicine (clinical biochemistry) at the University of Oslo (UiO) since 2007. From 1 August 2025 he will be Vice-Rector at UiO with special responsibilities for research and innovation in health and life sciences and the interaction with the university hospitals. He is a medical doctor by education (1986), a specialist in medical biochemistry (2004) and holds an adjunct position as a consultant at the Department of Medical Biochemistry at Oslo University Hospital. Berg holds a PhD from UiO (1995).

Berg has been Dean of Research at the Faculty of Medicine, UiO (2019-22), Head of Department at the Department of Medical Biochemistry, OUS (2015-19), Head of Research for the Division of Laboratory Medicine, OUS and UiO (2013-15). He has been Chairman of the Board of the Norwegian Centre for Molecular Medicine (NCMM) (2018-2024). His research interests are in diabetes and endocrinology. He chairs the expert council for the Norwegian Pediatric Diabetes Registry and is a member of the Norwegian Directorate of Health’s expert council for diagnostics and treatment of diabetes. Berg is editor-in-chief of the scientific journal The Scandinavian Journal of Clinical and Laboratory Investigations.

Wender Figved is Director of Medical Science, Research and Education at Oslo University Hospital. He is also Professor at the Institute of Clinical Medicine at the University of Oslo. In his role as Director in the CEO Executive Staff, Figved is a member of the executive management team at Oslo University Hospital. Figved has supervised four PhD candidates, and has extensive research experience from clinical studies, primarily within the field of orthopaedic surgery, multidisciplinary treatment and improvement methodology.

He is a certified specialist in orthopaedic surgery, has previously served as Head of Division of Orthopaedic surgery at Oslo University Hospital, and as head of the Ortohopaedic department at Bærum Hospital, Vestre Viken Hospital Trust. Figved holds a Master’s degree in Health Administration and Leadership, has served as head of the ortohopaedic professional council of Health South-East, and is a member of the Settlement and Coding Committee of the Norwegian Directorate of Health.

Mona-Elisabeth Rootwelt-Revheim is the head of the Department of Intervention at Oslo University Hospital and a professor at the Institute of Clinical Medicine at the University of Oslo. The Intervention Center is a research and development department focusing on research-driven innovation in collaboration with the industry, and the center has reported nearly 100 DOFIs related to medical technology in the last ten years.

Rootwelt-Revheim is an active researcher, primarily within basic and clinical studies related to technological translational research and radiotheranostics. She is a specialist in nuclear medicine and has previously been the head of Section for Nuclear Medicine at Oslo University Hospital. She collaborates particularly closely with the University of Pennsylvania after a research stay there in 2019.

She holds a master’s degree in health administration and has completed a research leadership program at the University of Oslo. Additionally, she has been the leader of the Professional Association in the Norwegian Medical Association and has held several other positions.

She has experience as a board member in both listed and unlisted companies.

Jan Terje Andersen is Professor of Biomedical Innovation at the University of Oslo and Research Group Leader at Oslo University Hospital, where he serves as Co-Director from June 2026. He heads the Laboratory of Adaptive Immunity and Homeostasis, which is part of PRIMA – a Centre of Excellence for Precision Immunotherapy funded by the Research Council of Norway, where he will serve as Co-Director from June 2026. His laboratory maintains extensive collaborations with biotechnology and pharmaceutical companies.

To date, Andersen has contributed to more than 80 innovations, 15 patent families and over 60 industry agreements spanning product sales, research collaborations and patent licensing. Among his recognitions are the Fridtjof Nansen Prize for Early Career Achievements, a Distinguished Innovator Grant from the Novo Nordisk Foundation, Inven2’s “Innovator of the Year” Award (2023), and the University of Oslo Innovation Award (2025). Andersen is an elected member of the Norwegian Academy of Science and Letters and co-founder of the biotech companies Authera AS and Superio Bio AS. He is actively engaged in public and strategic discussions on science and innovation policy.

Sveinung brings experience from business development, corporate finance as well as investment management. Sveinung has managed large turn-around processes, negotiated trade sales and been lead investor/board member in IPOs. He has extensive leadership-, board- and chair experience from VC-funds, listed companies, private companies and foundations. Sveinung has also held public engagements like heading “HelseOmsorg21-rådet” and been on the board of “Helse Bergen HF”. Prior to (re-)joining Sarsia Sveinung headed the largest research funding foundations of Norway.

Lars Kristian Eikvar is a medical doctor with a PhD in basic male reproductive endocrinology. He is a specialist in medical biochemistry and has worked on the implementation and application of biochemical markers for cardiac muscle damage and inflammation in atherosclerosis. After 12 years as a senior consultant at Ullevål University Hospital HF, he became the head of the Department of Medical Biochemistry at the merged Oslo University Hospital HF in 2010. From 2014 to 2019, he served as the clinic director for the Clinic for Diagnostics and Intervention, later the Clinic for Laboratory Medicine at the same institution. This position was combined with a role at the University of Oslo and leadership responsibility for the hospital’s largest university clinic.

He earned an Executive Master of Management from BI in 2012 and completed the National Executive Leadership Program for Health Enterprises. Additionally, he has served as chair of the Norwegian Association of Senior Hospital Physicians, as a central board member, and has held numerous other positions of trust within the Norwegian Medical Association. He has also been a board member of Helse Sør-Øst RHF and has held board positions in other foundations and limited companies. Lars Eikvar is currently the divisional director for research and diagnostics at Helse Sør-Øst RHF.

Anne Marie is an employee-elected board member.